We could not find any results for:
Make sure your spelling is correct or try broadening your search.
By Rebecca Thurlow SYDNEY--Mayne Pharma Group Ltd. (MYX.AU) said Wednesday it has launched its foam dermatology products Fabior and Sorilux in the U.S., after acquiring the marketing rights from...
/newsletter/barneyc/476/mayne-pharma-to-buy-42-drugs
Mayne Pharma Group Limited (“Mayne Pharma”) (ASX: MYX) has acquired a portfolio of dermatology foam products and related assets (“Foam Assets”) from GlaxoSmithKline (“GSK”) for US$50.1...
By Rebecca Thurlow SYDNEY--Mayne Pharma Group Ltd. (MYX.AU) acquired a portfolio of U.S. generic drugs from Teva Pharmaceutical Industries Ltd. (TEVA) and Allergan PLC (AGN) for US$652 million...
Australian shares are nearing their highest level since late October on Monday, though falling commodities prices muted gains triggered by stimulus hopes in Europe. The S&P/ASX 200 rose 0.4...
http://www.fool.com.au/2015/05/07/3-stocks-in-the-buy-zone-and-1-to-avoid/
By Michael Calia Actavis PLC raised its profit guidance for 2015, while acquisitions again helped drive revenue growth in the fourth quarter, as the company awaits the close of its deal to buy...
Actavis PLC (ACT) will sell the U.S. rights to an acne treatment as it seeks to refine its dermatology portfolio ahead of its purchase of Botox maker Allergan Inc. The Doryx deal, valued at about...
By Maria Armental and Robb M. Stewart Actavis PLC (ACT) will sell the U.S. rights to a acne treatment as it seeks to refine its dermatology portfolio ahead of its purchase of Botox maker Allergan...
HedgePath Pharmaceuticals Welcomes Three New Board Members Stefan Cross, Dr. Dana Ono and Mark Watson add significant biotechnology, capital markets and public accounting expertise to HPPI's...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.285 | 6.2363238512 | 4.57 | 4.9 | 4.43 | 82350 | 4.54297305 | DE |
4 | 0.245 | 5.31453362256 | 4.61 | 4.9 | 4.32 | 138157 | 4.5783459 | DE |
12 | 0.185 | 3.96145610278 | 4.67 | 5.34 | 3.74 | 164024 | 4.53780599 | DE |
26 | -2.105 | -30.2442528736 | 6.96 | 7.46 | 3.74 | 210586 | 5.11478638 | DE |
52 | 1.845 | 61.2956810631 | 3.01 | 7.46 | 2.75 | 240941 | 5.22212305 | DE |
156 | 4.545 | 1466.12903226 | 0.31 | 7.46 | 0.19 | 1824091 | 0.62796648 | DE |
260 | 4.255 | 709.166666667 | 0.6 | 7.46 | 0.19 | 2866890 | 0.47212033 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions